Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Shawn Donahue who wrote (195)	3/19/2009 3:19:26 PM
From: Shawn Donahue	Read Replies (1) \| Respond to of 237

Form 8-K for MULTICELL TECHNOLOGIES, INC. -------------------------------------------------------------------------------- 19-Mar-2009 Entry into a Material Definitive Agreement, Other Events Item 1.01 Entry Into a Material Definitive Agreement. On March 17 2009, MultiCell Technologies, Inc. ("MultiCell") executed Cooperative Research and Product Development Agreement (the "Agreement") with Maxim Biotech, Inc. ("Maxim") of Rockville, MD. Under the terms of the Agreement, Maxim and MultiCell will jointly research and develop products related to the isolation, characterization, differentiation and function of human hepatocyte cells and human liver stem cells. MultiCell and Maxim plan to develop, manufacture and market a family of reagents and reagent tool kits sold under MultiCell's brand name which target life science research ("LSR") application with a particular focus on products used for liver stem-related LSR applications. Item 8.01 Other Events On March 19, 2009, MultiCell issued a press release announcing the execution of the Agreement. A copy of this press release is attached hereto as Exhibit 99.1. This summary is qualified in its entirety by reference to Exhibit 99.1 to this current report. The press release and the information therein are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Exhibits Exhibit No. Description 10.1* Cooperative Research and Product Development Agreement between MultiCell Technologies, Inc. and Maxim Biotech, Inc. dated March 17, 2009. 99.1 Press Release dated March 19, 2009. * Confidential treatment has been requested with respect to certain portions of this exhibit pursuant to a request for confidential treatment under Rule 24b-2 promulgated under the Exchange Act. Omitted portions have been filed separately with the Securities and Exchange Commission. biz.yahoo.com